Tumor characteristics, radiation doses, and treatment responses
| Patient no. . | Histology (stage) . | Radiologically calculated splenic and lymph node volume, mL . | Maximum tumor diameter, mm . | No. of nodal sites . | FLIPI score . | Previous rituximab . | Previous response to chemotherapy (length in mo) . | Response to 131I-rituximab (length in mo) . | Cumulative whole-body dose, cGy . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Follicular (IV B) | 1320 | 60 | > 5 | 3 | Y (refractory) | PR (12) | CR (60) | 46.7 |
| 2 | Follicular (II B) | 147 | 30 | 3 | 0 | N | CR (5) | CR (60) | 43.1 |
| 3 | Transformed follicular (III A) | 290 | 30 | 4 | 1 | N | PR (10) | MR (17) | 38.4 |
| 4 | Follicular (IV A) | 1494 | 10 | > 5 | 3 | N | PR (10) | PR (23) | 41.0 |
| 5 | Follicular (IV A) | 489 | 23 | > 5 | 3 | N | PR (7) | CR (12) | 75.3 |
| 6 | Follicular (IV B) | 838 | 32 | > 5 | 2 | Y (refractory) | PR (6) | PR (13) | 72.5 |
| 7 | Follicular (IV A) | 662 | 49 | > 5 | 2 | Y | PR (4) | PR (7; transformed at relapse) | 71.1 |
| 8 | Transformed follicular (IV A) | 630 | 42 | > 5 | 3 | N | Refractory to treatment | PR (7) | 79.5 |
| 9 | Small lymphocytic (IV A) | 484 | 45 | 4 | 3 | N | CR (14) | CR (50+) | 106.5 |
| 10 | Transformed follicular (II B) | 308 | 32 | 4 | 1 | Y | PR (2) | PR (25) | 105.2 |
| 11 | Follicular (IV A) | 842 | 42 | > 5 | 2 | Y (refractory) | MR (6) | CR (45+) | 106.0 |
| 12 | Follicular (IV B) | 1451 | 73 | > 5 | 3 | Y | PR (11) | PR (25) | 95.6 |
| 13 | Follicular (IV A) | 127 | 37 | 3 | 1 | Y (refractory) | PR (3) | CR (41+) | 141.3 |
| 14 | Follicular (IV A) | 676 | 53 | > 5 | 3 | N | PR (7) | CR (28+) | 131.8 |
| 15 | Follicular (III A) | 169 | 23 | > 5 | 2 | N | PR (3) | CR (27+) | 138.72 |
| 16 | Follicular (IV B) | 679 | 58 | > 5 | 2 | N | CR (22) | PR (20) | 128.3 |
| Patient no. . | Histology (stage) . | Radiologically calculated splenic and lymph node volume, mL . | Maximum tumor diameter, mm . | No. of nodal sites . | FLIPI score . | Previous rituximab . | Previous response to chemotherapy (length in mo) . | Response to 131I-rituximab (length in mo) . | Cumulative whole-body dose, cGy . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Follicular (IV B) | 1320 | 60 | > 5 | 3 | Y (refractory) | PR (12) | CR (60) | 46.7 |
| 2 | Follicular (II B) | 147 | 30 | 3 | 0 | N | CR (5) | CR (60) | 43.1 |
| 3 | Transformed follicular (III A) | 290 | 30 | 4 | 1 | N | PR (10) | MR (17) | 38.4 |
| 4 | Follicular (IV A) | 1494 | 10 | > 5 | 3 | N | PR (10) | PR (23) | 41.0 |
| 5 | Follicular (IV A) | 489 | 23 | > 5 | 3 | N | PR (7) | CR (12) | 75.3 |
| 6 | Follicular (IV B) | 838 | 32 | > 5 | 2 | Y (refractory) | PR (6) | PR (13) | 72.5 |
| 7 | Follicular (IV A) | 662 | 49 | > 5 | 2 | Y | PR (4) | PR (7; transformed at relapse) | 71.1 |
| 8 | Transformed follicular (IV A) | 630 | 42 | > 5 | 3 | N | Refractory to treatment | PR (7) | 79.5 |
| 9 | Small lymphocytic (IV A) | 484 | 45 | 4 | 3 | N | CR (14) | CR (50+) | 106.5 |
| 10 | Transformed follicular (II B) | 308 | 32 | 4 | 1 | Y | PR (2) | PR (25) | 105.2 |
| 11 | Follicular (IV A) | 842 | 42 | > 5 | 2 | Y (refractory) | MR (6) | CR (45+) | 106.0 |
| 12 | Follicular (IV B) | 1451 | 73 | > 5 | 3 | Y | PR (11) | PR (25) | 95.6 |
| 13 | Follicular (IV A) | 127 | 37 | 3 | 1 | Y (refractory) | PR (3) | CR (41+) | 141.3 |
| 14 | Follicular (IV A) | 676 | 53 | > 5 | 3 | N | PR (7) | CR (28+) | 131.8 |
| 15 | Follicular (III A) | 169 | 23 | > 5 | 2 | N | PR (3) | CR (27+) | 138.72 |
| 16 | Follicular (IV B) | 679 | 58 | > 5 | 2 | N | CR (22) | PR (20) | 128.3 |